Group 1 - Yishitong plans to repurchase shares worth between 30 million to 55 million yuan at a price not exceeding 40.69 yuan per share, intended for employee stock ownership plans or equity incentives [1] - Guoyao Modern's subsidiary has received approval for a sodium bicarbonate injection to increase specifications and pass consistency evaluation [2] - Xinjing plans to reduce its shareholding by up to 1.2 million shares, accounting for 0.78% of the total share capital, between October 14, 2025, and January 13, 2026 [2] Group 2 - Jinfeikeda intends to apply for an additional credit limit of up to 60 million yuan from Jiangsu Financial Leasing [3] - Boshi Co. signed a project contract worth 235 million yuan with Guoneng Yulin Chemical for a three-year service period starting from October 31, 2025 [4] - Luan Energy reported a coal sales volume of 3.78 million tons in August, a decrease of 13.70% year-on-year [6] Group 3 - Shengnong Development achieved sales revenue of 1.857 billion yuan in August, a year-on-year increase of 19.11% [8] - Huading Co. plans to transfer 9.26% of its shares through public solicitation of transferees [10] - China Metallurgical Group's new contract amount from January to August decreased by 18.2% year-on-year, totaling 679.57 billion yuan [12] Group 4 - Longjing Environmental plans to invest approximately 3.99 billion yuan in the construction of a hydropower station project in the Democratic Republic of the Congo [14] - Longjing Environmental also plans to invest 2.391 billion yuan in an integrated energy station project, expected to be operational by the second quarter of 2026 [15] - Transsion Holdings has set the transfer price for its shares at 81.81 yuan per share, with a subscription rate of 1.15 times [17] Group 5 - Sinopec Oilfield Services won a bid for a natural gas pipeline project with a contract value of 858 million yuan [18] - Huaitian Thermal Power received a warning letter from the Liaoning Securities Regulatory Bureau for information disclosure violations [20] - China Nuclear Engineering signed new contracts totaling 96.633 billion yuan as of August [22] Group 6 - Shanghai Mechanical plans to publicly transfer 67% of its stake in Simic Welding Materials, with an estimated value of 291 million yuan [24] - Zhongke Environmental appointed Tang Xia as the new deputy general manager [26] - Baiyang Pharmaceutical signed a strategic cooperation agreement with Jikun Pharmaceutical for a drug project [28] Group 7 - Jinsong New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for fundraising irregularities [27] - Weitang Industrial obtained a national invention patent for a battery tray welding deformation control device [29] - Dongsoft Carrier secured two national invention patents related to energy management and voltage regulation circuits [30] Group 8 - Lian De Equipment won a bid for the BOE AMOLED production line project with a total amount of 201 million yuan [31] - Jingjiawei signed a strategic cooperation agreement with Anchaoyun to develop high-performance cloud desktop solutions [32] - Chuaning Biological received approval for a 1 billion yuan medium-term note registration [34] Group 9 - Jifeng Co. plans to reduce its shareholding by up to 2% through block trading [36] - Taihe Intelligent plans to transfer 5.79% of its shares to Sunshine New Energy Development Co., Ltd. [36] - Yangmei Chemical will change its stock name to "Luhua Technology" starting September 17, 2025 [38] Group 10 - ST Songfa's subsidiary signed contracts for the construction of four container ships, with a total value of approximately 300 to 500 million USD [40] - Green Energy Huichong plans to establish a joint venture with Xianyang Economic Development Group with a registered capital of 250 million yuan [42] - Baiyao Tai received a milestone payment of 5.4 million USD from Intas Pharmaceuticals [38]

百奥泰生物制药股份有限公司 自愿披露关于与 Intas Pharmaceuticals Ltd.就 BAT2506（戈利木单抗）注射液签署授权许可与商 业化协议收到里程碑付款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 2 月 26 日召开 2025 年第一次临时股东大会，会议表决通过 了《关于就 BAT2506（戈利木单抗）签署授权许可与商业化协议的议案》，该协 议于当日起生效。 证券代码：688177 证券简称：百奥泰 公告编号：2025-062 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于北京时间 2025 年 2 月 10 日与 Intas Pharmaceuticals Ltd.（以下简称"Intas"）签署授权许可 与商业化协议，将公司的 BAT2506（戈利木单抗）注射液在美国市场的独占的产 品商业化权益有偿许可给 Intas（以下简称"协议"或"本协议"）。百奥泰将负责 研发、生产及商业化供应，Intas 将通过其美国子公司 Accord BioPharm ...

Core Viewpoint - The company announced the approval of a licensing and commercialization agreement for BAT2506 (Golimumab) during its first extraordinary general meeting of 2025, which will take effect immediately [1] Group 1: Financial Details - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount that will be further reduced by bank fees [1] - The total amount received in RMB is approximately 38.36 million, calculated using the exchange rate of 7.1034 RMB per USD as of September 11, 2025 [1] Group 2: Regulatory Status - As of the date of the announcement, the company has submitted applications for the marketing authorization of BAT2506 (Golimumab) to the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), all of which have been accepted [1]

Core Insights - The company has signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. for the exclusive commercialization rights of BAT2506 (Golimumab) injection in the U.S. market [1] - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount of approximately RMB 38.36 million [1] - This payment will enhance the company's cash reserves, supporting future pipeline research and internationalization strategies [1]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-061 百奥泰生物制药股份有限公司 自愿披露关于 Qletli®（阿达木单抗注射液）获得 英国 MHRA 上市批准的公告 现将相关情况公告如下： 一、 药品相关情况 （一） 药品名称：阿达木单抗注射液 （二） 商品名称：Qletli® （三） 剂型规格： 预充式注射器注射液：40mg/0.8mL （四） 成人适应症：类风湿关节炎、多关节型幼年特发性关节炎、与附着 点炎症相关的关节炎、强直性脊柱炎、无强直性脊柱炎影像学证据的中轴型脊 柱关节炎、银屑病关节炎、银屑病、化脓性汗腺炎、克罗恩病、溃疡性结肠炎、 葡萄膜炎；儿童适应症：多关节型幼年特发性关节炎、与附着点炎症相关的关 节炎、儿童斑块状银屑病、儿童克罗恩病、儿童溃疡性结肠炎、儿童葡萄膜炎 二、 药品其他相关情况 BAT1406 是百奥泰自主研发的阿达木单抗生物类似药，是由 CHO 细胞表 达的重组全人源单克隆抗体，通过与 TNF-α特异性结合并中和其生物学功能， 阻断其与细胞表面 TNF-α受体的相互作用，从而阻断 TNF-α的致炎作用。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载 ...

Core Viewpoint - Company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Qletli (BAT1406), a biosimilar of adalimumab, which is expected to enhance the company's international market presence and positively impact long-term operational performance [1] Group 1 - Qletli (BAT1406) is a fully human monoclonal antibody developed by the company, expressed in CHO cells, that specifically binds to and neutralizes TNF-α, blocking its inflammatory effects [1] - The approval allows the company to expand its product offerings in the UK market, thereby increasing its international influence [1] - The drug is indicated for various adult conditions including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, among others [1] Group 2 - Pediatric indications for Qletli include juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease [1] - The approval is expected to have a positive impact on the company's long-term business performance [1]

Core Viewpoint - The company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilar drug Qletli® (BAT1406, Adalimumab injection) [1] Group 1: Product Approval - Qletli® is a biosimilar of Adalimumab developed by the company, expressed in CHO cells as a recombinant fully human monoclonal antibody [1] - The drug works by specifically binding to TNF-α, neutralizing its biological function, and blocking its interaction with cell surface TNF-α receptors, thereby inhibiting the inflammatory effects of TNF-α [1] - The approval allows the company to expand its product offerings in the UK market, enhancing its international influence and potentially positively impacting long-term operational performance [1] Group 2: Indications - Adult indications for Qletli® include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, spondyloarthritis related to enthesitis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and uveitis [1] - Pediatric indications include polyarticular juvenile idiopathic arthritis, spondyloarthritis related to enthesitis, pediatric plaque psoriasis, pediatric Crohn's disease, pediatric ulcerative colitis, and pediatric uveitis [1]

Core Viewpoint - Company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilar drug Qletli® (BAT1406, Adalimumab injection) [1] Group 1: Product Development - BAT1406 is a biosimilar of Adalimumab developed independently by the company, expressed in CHO cells as a recombinant fully human monoclonal antibody [1] - The drug works by specifically binding to TNF-α and neutralizing its biological function, blocking its interaction with cell surface TNF-α receptors, thereby inhibiting the inflammatory effects of TNF-α [1] Group 2: Market Impact - With the approval from the UK MHRA, Qletli® can now be marketed and sold in the UK, further expanding the company's overseas product offerings [1] - This approval is expected to enhance the company's international influence and may have a positive impact on its long-term operational performance [1]

Core Viewpoint - The company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Qletli (BAT1406, Adalimumab injection) [1] Group 1: Product Development - Qletli is a biosimilar of Adalimumab developed independently by the company, expressed in CHO cells as a recombinant fully human monoclonal antibody [1] - The mechanism of action involves specific binding to TNF-α, neutralizing its biological function, and blocking its interaction with cell surface TNF-α receptors, thereby inhibiting the inflammatory effects of TNF-α [1] Group 2: Market Impact - With the approval from the UK MHRA, the company can now sell Qletli in the UK, expanding its overseas product offerings [1] - This approval is expected to enhance the company's international influence and positively impact its long-term operational performance [1]